Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001 Meeting Abstract
| Authors: | Rizvi, N. A.; Garon, E. B.; Leighl, N.; Hellmann, M. D.; Patnaik, A.; Gandhi, L.; Eder, J. P.; Rangwala, R. A.; Lubiniecki, G.; Zhang, J.; Emancipator, K.; Roach, C. M.; Rutledge, R.; Hui, R. N.; Ahn, M. J.; Horn, L.; Felip, E.; Costa, E. C. |
| Abstract Title: | Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001 |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901739 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.8026 |
| Notes: | Meeting Abstract: 8026 -- Source: Wos |
